Lung Cancer Mutation Consortium Protocol
|ClinicalTrials.gov Identifier: NCT01014286|
Recruitment Status : Active, not recruiting
First Posted : November 16, 2009
Last Update Posted : August 30, 2017
|Condition or disease|
|Adenocarcinoma of Lung, Stage IV|
|Study Type :||Observational|
|Actual Enrollment :||1100 participants|
|Official Title:||Lung Cancer Mutation Consortium Protocol|
|Study Start Date :||September 2009|
|Estimated Primary Completion Date :||December 2018|
|Estimated Study Completion Date :||December 2018|
Stage IV adenocarcinoma who have undergone biopsy with remnant tissue.
- Frequency of oncogenic mutations in patients with advanced adenocarcinoma of the lung. [ Time Frame: Five years ]The primary objective of this protocol is to determine the frequency of oncogenic mutations in patients with advanced adenocarcinoma of the lung.
- Rate of oncogenic mutations in patients with advanced adenocarcinoma of the lung. [ Time Frame: Five years ]The primary endpoint of this protocol is the mutation rate.
- Associations between each mutation and clinical outcomes. [ Time Frame: Two years ]The secondary objectives of this protocol are to study the associations between each mutation and clinical outcomes, e.g., survival, clinical features, e.g. smoking status, age, and other mutation.
Biospecimen Retention: Samples With DNA
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01014286
|United States, Colorado|
|University of Colorado Denver Cancer Center|
|Aurora, Colorado, United States, 80045|
|Study Director:||Paul Bunn, M.D.||University of Colorado, Denver|